Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.

• Main Authors: Asrat Hailu (Author), Ahmed Musa (Author), Monique Wasunna (Author), Manica Balasegaram (Author), Sisay Yifru (Author), Getahun Mengistu (Author), Zewdu Hurissa (Author), Workagegnehu Hailu (Author), Teklu Weldegebreal (Author), Samson Tesfaye (Author), Eyasu Makonnen (Author), Eltahir Khalil (Author), Osama Ahmed (Author), Ahmed Fadlalla (Author), Ahmed El-Hassan (Author), Muzamil Raheem (Author), Marius Mueller (Author), Yousif Koummuki (Author), Juma Rashid (Author), Jane Mbui (Author), Geoffrey Mucee (Author), Simon Njoroge (Author), Veronica Manduku (Author), Alice Musibi (Author), Geoffrey Mutuma (Author), Fredrick Kirui (Author), Hudson Lodenyo (Author), Dedan Mutea (Author), George Kirigi (Author), Tansy Edwards (Author), Peter Smith (Author), Lawrence Muthami (Author), Catherine Royce (Author), Sally Ellis (Author), Moses Alobo (Author), Raymond Omollo (Author), Josephine Kesusu (Author), Rhoda Owiti (Author), John Kinuthia (Author), Leishmaniasis East Africa Platform (LEAP) (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2010-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious first-line treatment w...